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ORIGINAL RESEARCH
Untargeted Lipidomics Reveals a Specific 
Enrichment in Plasmalogens in Epicardial 
Adipose Tissue and a Specific Signature  
in Coronary Artery Disease
Magali Barchuk, Anne Dutour, Patricia Ancel, Ljubica Svilar, Veronica Miksztowicz, Graciela Lopez, Miguel Rubio,  
Laura Schreier, Juan Patricio Nogueira, René Valero, Sophie Beliard, Jean Charles Martin, Gabriela Berg,* Bénédicte Gaborit*
OBJECTIVE: Epicardial adipose tissue (EAT) is an active endocrine organ that could contribute to the pathophysiology of 
coronary artery disease (CAD) through the paracrine release of proatherogenic mediators. Numerous works have analyzed 
the inflammatory signature of EAT, but scarce informations on its lipidome are available. Our objective was first to study the 
differences between EAT and subcutaneous adipose tissue (SAT) lipidomes and second to identify the specific untargeted 
lipidomic signatures of EAT and SAT in CAD.
APPROACH AND RESULTS: Subcutaneous and EAT untargeted lipidomic analysis was performed in 25 patients with CAD and 14 
patients without CAD and compared with paired plasma lipidomic analysis of isolated VLDL (very low-density lipoprotein) 
and HDL (high-density lipoprotein). Lipidomics was performed on a C18 column hyphenated to a Q-Exactive plus mass 
spectrometer, using both positive and negative ionization mode. EAT and SAT had independent lipidomic profile, with 95 lipid 
species differentially expressed and phosphatidylethanolamine 18:1p/22:6 twenty-fold more expressed in EAT compared 
with SAT false discovery rate =3×10−4). Patients with CAD exhibited more ceramides (P=0.01), diglycerides (P=0.004; 
saturated and nonsaturated), monoglycerides (P=0.013) in their EAT than patients without CAD. Conversely, they had 
lesser unsaturated TG (triglycerides; P=0.02). No difference was observed in the 295 lipid species found in SAT between 
patients with and without CAD. Fifty-one lipid species were found in common between EAT and plasma lipoproteins. TG 
18:0/18:0/18:1 was found positively correlated (r=0.45, P=0.019) in EAT and HDL and in EAT and VLDL (r=0.46, P=0.02).
CONCLUSIONS: CAD is associated with specific lipidomic signature of EAT, unlike SAT. Plasma lipoprotein lipidome only partially 
reflected EAT lipidome.
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The prevalence of obesity and type 2 diabetes mel-litus has considerably increased these recent years. These metabolic diseases are strongly associated 
with cardiovascular diseases, contributing to global mor-
tality burden.1 Organ-specific adiposity has renewed 
growing interest in that it probably contributes to the 
pathophysiology of cardiometabolic diseases.2 However, 
the molecular changes in adipose tissue that promote 
these disorders are not completely understood and, in 
particular, the specific role of cardiac adiposity. Epicardial 
adipose tissue (EAT) is the visceral fat deposit over the 
heart, located between the myocardium and the visceral 
pericardium.3 Over the last years, the perception of this 
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fat storage depot. Indeed, it is now widely recognized 
to be an extremely active endocrine organ, producing 
cytokines, adipokines, chemokines that could either be 
protective or harmful depending on the local microenvi-
ronment.4,5 This richness probably highlights the complex 
cellularity and cross-talk between EAT and neighbor-
ing structures. EAT metabolism is uniquely regulated 
because of high basal rates of fatty acid uptake, insulin-
induced lipogenesis, and high fatty acid breakdown.6 EAT 
may act as a local energy store for cardiac muscle and 
has a protective role against elevated levels of free fatty 
acid in the coronary circulation.7 However, amount and 
type of fatty acids stored could also play a role in the 
onset and development of atherosclerosis. Interestingly, 
some gas-liquid chromatography based studies showed 
an increase in some saturated (C14:0, C16:0, and C18:0) 
and conjugated linoleic fatty acids and a decrease in 
unsaturated fatty acids in EAT of patients with type 2 
diabetes mellitus.8,9 Recent studies have shown that the 
volume of epicardial fat was strongly positively correlated 
with the presence of coronary artery disease (CAD) and 
predicted future coronary events at 8 years.10,11 However, 
there is scarce information about the lipidome differ-
ences between EAT and subcutaneous adipose tissue 
(SAT) of patients with CAD and the comparison with the 
lipidome of TRL (TG-rich lipoproteins remnants), and 
HDL (high-density lipoprotein).
Unlike genes and proteins, metabolites serve as direct 
signatures of biochemical activity, being, therefore, easier 
to correlate with the phenotype. In this context, metabo-
lomics and its derivative lipidomics have become pow-
erful approaches opening a window to mechanistically 
investigate how biochemistry relates to clinical pheno-
type.12,13 Targeted and untargeted lipidomics are the 2 
main techniques applied for lipid species analyses of 
various biological samples, including adipose tissue. The 
targeted approach aims to identify specific groups of lip-
ids selected beforehand while untargeted analysis char-
acterizes overall detectable lipid content. Therefore, the 
aim of this study was to identify the specific untargeted 
lipidomic signature of EAT in the context of CAD and to 
compare it with the plasma lipidomic signature of TRL.
MATERIAL AND METHODS
The data that support the findings of this study are available 
from the corresponding author upon reasonable request.
Patients
The study included 39 consecutive patients undergoing coro-
nary artery bypass graft (n=25) or valve replacement (n=14) 
at the Cardiac Surgery Division of Hospital de Clinicas José 
de San Martín, University of Buenos Aires. All patients gave 
written informed consent, and the study was approved by the 
Ethical Review Committee of the Faculty of Pharmacy and 
Biochemistry, University of Buenos Aires and by the Ethical 
Review Committee of the Hospital de Clínicas José de San 
Martín. Paired adipose tissue samples were obtained from tho-
racic subcutaneous (parasternal region) and EAT (at the origin 
of the right coronary artery) during elective surgical procedure 
and before the extracorporeal circulation was started. Samples 
were washed, fragmented, and immediately flashfrozen in 
liquid nitrogen before being stored at −80°C. Clinical data 
were obtained upon admission to the hospital before surgery. 
Diagnosis of CAD was based on coronarography. Reductions 
in luminal coronary artery diameters >70% were considered 
significant. Previous diagnosis of type 2 diabetes mellitus was 
assessed according to the American Diabetes Association.14 
Patients without CAD were randomly selected among patients 
who did not undergo coronary artery bypass graft intervention. 
Nonstandard Abbreviations and Acronyms
CAD coronary artery disease
Cer ceramide
DG diglycerides




MCP-1 monocyte chemotactic protein-1
MS mass spectrometry
PLS partial least squares
SAT subcutaneous adipose tissue
TG triglycerides
TNF tumor necrosis factor
TRL TG-rich lipoproteins remnants
VLDL very-low-density lipoprotein
Highlights
• Epicardial adipose tissue (EAT) has an independent 
lipidomic profile compared to subcutaneous adipose 
tissue.
• We uniquely report a specific enrichment in phos-
phatidylethanolamine, phosphatidylcholine, short- 
and medium-chain fatty acids in TG (triglyceride) in 
the EAT compared to subcutaneous adipose tissue. 
EAT showed an increase in plasmalogens that could 
reflect a specific thermogenic activity compared to 
subcutaneous adipose tissue.
• In coronary artery disease, EAT had a specific lipi-
domic signature with a significant increase in proin-
flammatory lipids, such as sphingolipids (ceramides), 
diglycerides and monoglycerides, and a decrease, in 
unsaturated TG, in contrast to subcutaneous adi-
pose tissue.
• Plasma lipoprotein (HDL [high-density lipoprotein] 
and VLDL [very low-density lipoprotien]) lipidome 
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These patients had no clinical signs of CAD and showed nor-
mal coronary arteries on angiography. The weight and height 
of each participant were measured, and body mass index and 
blood pressure were recorded in all cases. The following exclu-
sion criteria were considered for both groups: previous heart 
surgery, concomitant infective diseases, alcohol intake >20 
g/d, recent history of acute illness, end-stage organ failure, and 
any other condition that may interfere with the results.
VLDL and HDL Isolation
VLDL (density <1.006 g/mL) and HDL (density: 1.063–1.210 
g/mL) were isolated by sequential preparative ultracentrifuga-
tion in a Beckman XL-90 using a fixed-angle rotor type 90 Ti at 
105.000g, for 18 hours, at 18°C and 4°C, respectively.15 Purity 
of lipoproteins was tested by agarose gel electrophoresis, as 
previously described.16
Determination of Lipidomic Profile
Lipid Extraction
For lipid extraction, methyl-terbutyl ether was used as the 
extraction solvent, as fully described by Matyash et al.17 A vol-
ume of 200 µL of VLDL fraction, 400 µL of the HDL fraction 
was extracted. Before extraction, 10 mg of adipose tissue (EAT 
or SAT) were cut in small pieces.
Briefly, 1.5 mL of methanol and 5 mL of methyl-terbutyl ether 
were added to each sample and vortexed for 1 hour. Subsequently, 
1.25 mL of deionized water was added to each tube and incu-
bated for 10 minutes at room temperature, after homogenization. 
The tubes were then centrifuged for 10 minutes at 1000 rpm 
and 10°C, and the upper organic phase was separated in another 
tube. The lower phase was washed with 2 mL of a methyl-terbutyl 
ether /methanol/water mixture (20:6:5, v/v/v) and centrifuged as 
previously described for a second extraction. The upper organic 
phase was pooled with the first one obtained in previous step. 
Solvent was evaporated under a stream of nitrogen and dried lipid 
extract were stored at −80°C until processing. Lipid extracts were 
then resuspended in 200 µL of a chloroform/methanol/distilled 
water mixture (40:20:3, v/v/v).
Liquid Chromatography
The UHPLC separation was performed on a DionexUltiMate 
3000 device (Thermo Fisher Scientific, Courtaboeuf, France) 
using the Accucore C18 column (150×2.1 mm, 2.6 µm).
The column temperature was kept at 45°C. Mobile phase 
A contained 10 mmol/L ammonium formate in 60% acetoni-
trile and 0.1% formic acid, and mobile phase D contained a 
10 mmol/L ammonium formate in acetonitrile:propan-2-ol (1:9, 
v/v) mixture with 0.1% formic acid. The flow rate was 0.4 mL/
min. The elution gradient was: 35% D at the beginning, 35% 
to 60% D for 4 minutes, 60% to 85% B for 8 minutes, 85% to 
100% B for 9 minutes, 100% B for 3 minutes, and 35% B for 
4 minutes. The injection volume was 2 µL.
Samples were randomly assigned to the injection table and 
interspaced (1 of 5) with quality control samples made up of 
a pool of each sample or solvent for blank. All samples were 
analyzed in a single series for HDL and VLDL or EAT and SAT.
Mass Spectrometry
Mass spectrometry (MS) spectra of the analyzed samples were 
acquired using a Q-Exactive Plus (Thermo Fisher) spectrometer 
with electrospray ionization in positive and negative modes and 
with a full scan (m/z 250 to 1200) according to the methodol-
ogy detailed by Breitkopf et al.18 Briefly, the drying temperature 
was set to 285°C, the capillary voltage was set to 3000 V. The 
resolution of the orbitrap mass analyzer was set to of 4 scans/s 
at 35 000 resolution and injection time of 200 ms.
Full MS spectra were acquired for each sample. Data 
Dependent Analysis Top 15 MS/MS were used for the acqui-
sition of the MS/MS spectra and performed in one-tenth of 
the samples. Each sample was acquired in positive and nega-
tive ionization modes separately to obtain as much structural 
information as possible. This method consists in detecting the 
most abundant ionic species in the primarily acquired full MS 
spectra. These 15 ionic species are consequently fragmented 
by higher collision-induced dissociation in the next 15 scans 
finishing the cycle with the last MSMS. New cycle starts with a 
new full MS scan and another 15 MS/MS scans for the next 
15 ionic species.
Data Treatment
Once the data of the molecular ions corresponding to the 
metabolites were acquired, the resulting spectra were visually 
inspected to control the signal intensity. The acquired spectra 
were divided into 2 groups:
Spectra used for the creation of a data matrix, for use in the 
XCMS software: the 3-dimensional raw data (m/z, retention 
time and ion intensity) obtained from the liquid chromatography-
MS analysis were deconvolved in a composite matrix of chro-
matographic peaks aligned in time and a mass-to-charge ratio 
(m/z) with the intensity of the respective ions. Proteo Wizard 
MS Convert software was used to convert the original data files 
(*.raw) into more interchangeable formats and centroid mode (*.
mzXML) for both analyzed positive and negative spectra. Data 
processing were performed using the open-source XCMS soft-
ware as previously described.19
Peak detection was achieved using the centWave method. 
Maximum and minimum peak width were 2 and 60 seconds, 
S/N threshold was maintained at 3, where the noise was 12 000 
for positive and 6000 for negative ionization mode, difference 
of m/z at −0.00005, maximal deviation of m/z in 2 consecutive 
scans 5 ppm. Detection of peak in 4 consecutive scans with 
minimal intensity 60 000 was considered as a real peak. Peak 
alignment between samples was achieved using the Obiwarp 
method and for grouping peaks method density was applied.
Once the matrix of raw data was obtained, several filters 
were applied to eliminate the analytical background and cor-
rect the analytical drift. All signals from electronic noise, as well 
as null samples, were removed manually. Unstable peaks and 
redundant information (fragments, adducts, and isotopes) were 
eliminated by using the coefficients of variation of the peaks 
applied to the control samples.
Spectra used to create a database using LipidSearch soft-
ware (v4.0, Thermofischer scientific): an in silico database was 
built using LipidSearch software, based on the MS/MS spectra 
recorded in the samples. This software contains the in silico 
database of different lipid families, based on their specific frag-
mentation mode and the length of the FA chains. This theoreti-
cal fragmentation model corresponds to the MS/MS spectra of 
the tissue extracts, and the annotations of various fragmented 
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In most of the signals, it was possible to identify the corre-
sponding lipid species. Once the lipids in the LipidSearch matrix 
were identified, the resulting m/z and retention time pairs were 
matched to that of obtained with XCMS using the data inhouse 
tool of the Galaxy Workflow4Metabolomics web application,20 
to identify the lipid species and their intensities in each sample. 
A final filter was applied to this last database, using parameters 
such as relative SD, duplicates in both modes, choice of the 
most stable, and most intense peak for each lipid among others. 
This curated and annotated matrix containing semi-quantitative 
value for each lipid per sample was used for statistical analyses.
Statistical Analysis
Anthropometric and biochemical parameters were expressed as 
mean ± SD or median and 25th to 75th percentile. Lipid species 
relative quantification was expressed in percentages ± SEM. 
Principal component analyses, partial least squares (PLSs), and 
orthogonal PLSs regression analyses of autoscaled values were 
performed with Simca P12 software (Sartorius Stedim Biotech, 
Göttingen, Germany) or MetaboAnalyst (http://www.metaboan-
alyst.ca/)21 and GraphPad Prism 6.0. Pathways enrichment was 
performed with MetaboAnalyst using small molecule pathway 
database. Cooman plot analysis was performed to determine 
the effect of gender on the EAT lipidome. Class membership 
was tested against the 2 principal component analyses mod-
els in a SIMCA procedure. The distance from each model is 
computed (DmodX1 and DmodX2, respectively) and plotted. 
The Dcrit value for each model defines the class. Thus, there 
were 4 possible outcomes: an individual could be predicted 
to be males, females only, neither or both (eg, undefined). The 
gaussian distribution of the data sets was assessed by Shapiro-
Wilk normality test. The significant differences between groups 
were detected by Student 2-sample t test or Wilcoxon rank-
sum test when appropriate. The Benjamini Yekutieli procedure 
for controlling the false discovery rate was applied. P<0.05 was 
considered statistically significant.
RESULTS
Thirty-nine patients were included (25 CAD and 14 
non-CAD) patients with a mean age of 63.8±11.3 years 
(CAD group) versus 64.1±14.4 years (non-CAD group, 
P=NS) and a mean body mass index of 28.6±4.6 (CAD) 
versus 29.9±6.6 kg/m2 (non-CAD), respectively (P=NS). 
As expected, patients with CAD had more cardiovascular 
risk factors than patients without CAD (Table 1).
Representative MS/MS spectra for one CAD and one 
non-CAD subject in EAT, SAT and associated extracted 
chromatograms of 4 representative lipids are shown 
in Figure I in the Data Supplement. Two-hundred and 
ninety-five lipid species were identified in the adipose 
tissues, with as expected TGs (triglycerides) as the major 
component (96.8% of lipid species for EAT and SAT).
Differences Between Epicardial and SAT 
Lipidomes
A PLS regression calculated between paired EAT and 
SAT total lipidomic profiles (n=39 whole group) showed 
no significant overarching relationships between the 2 
adipose tissues. In addition, orthogonal PLS paired sta-
tistics showed that EAT and SAT had a totally different 
lipidomic profile (Figure 1), with 95 lipid species differ-
entially expressed between the 2 adipose tissues (false 
discovery rate <0.05; Table 2). The samples were well 
separated with respect to adipose tissue location, the lat-
ter explaining 62% of lipid species variance (Figure 1). 
In particular, phosphatidylethanolamine 18:1p/22:6 was 
>20-fold expressed in EAT compared with SAT, false 
discovery rate 3×10−4 (Table 2). EAT had also the high-
est content in C20/C22 polyunsaturated fatty acids lipid 
species, including C22:6n-3 containing lipids. It was also 
wealthier in unusual adipose short (C4/C6) to medium 
(C10/C12) chain saturated fatty acids TG species than 
SAT. Conversely, EAT had the lowest content in C18:1 and 
C18:2 fatty acids TGs, as well as in less usual adipose very 
long-chain (>C20–C28) saturated fatty acids (Table 2).
An increase in sphingolipids (ceramides [Cer 
d18:2/18:0, Cer d18:1/18:0, and Cer d18:1/24:1] and 
sphingomyelin [sphingomyelin d41:1]) was observed in 
Table 1. Characteristics of the Studied Population
Parameters NCAD (n=14) CAD (n=25) P Value
Age, y 64.1±14.4 63.8±11.3 NS
Sex, n (% men) 7 (50) 23 (92) 0.005
Body mass index, kg/m2 29.9±6.6 28.6±4.6 NS
Hypertension, n (%) 9 (64) 17 (68) NS
Ex-smokers, n (%) 2 (14) 12 (48) 0.044
Systolic blood pressure, 
mm Hg
120±19 132±18 NS
Diastolic blood pressure, 
mm Hg
60 (60–72) 71 (60–80) NS
Atrial fibrillation, n (%) 0 (0) 1 (4) NS
Valvular disease, n (%) 14 (100) 0 (0) <0.001
 Aortic/mitral 12 (85)/2 (15)   
 Stenosis/insufficiency 8 (57)/6 (43)   
Biological parameters
 Glycemia, g/L 0.90 (0.85–0.94) 1.07 (0.94–1.37) <0.001
 hsCRP, mg/L 0.61±0.21 2.96±1.41 <0.001
 Uric acid, µmol/L 293.7±53.1 289.4±83.9 NS




 Total cholesterol 1.35 (1.04–1.73) 1.21 (1.01–1.37) NS
 Triglycerides 0.93 (0.64–1.39) 1.37 (0.95–1.73) 0.040
 LDL-cholesterol 1.00 (0.67–1.30) 0.72 (0.53–0.86) NS
 HDL-cholesterol 0.38 (0.30–0.44) 0.30 (0.25–0.39) NS
 Non–HDL-cholesterol 0.96 (0.71–1.37) 0.85 (0.65–0.98) NS
 TG-rich lipoproteins 0.08 (0.04–0.11) 0.17 (0.08–0.21) 0.001
  Lipid ratio (total Chol/
HDL Chol)
3.43 (2.99–4.92) 4.03 (3.10–4.68) NS
CAD indicates coronary artery disease; HDL, high-density lipoprotein; LDL, 





 http://ahajournals.org by on M
arch 1, 2020
ORIGINAL RESEARCH - AL
Barchuk et al Lipidomics and Epicardial Adipose Tissue
Arterioscler Thromb Vasc Biol. 2020;40:00–00. DOI: 10.1161/ATVBAHA.120.313955 April 2020  5
EAT compared with SAT (P=0.02 and P=0.005). EAT was 
3-fold richer in glycerophosphatidylcholines (P<0.001) 
and 2-fold richer in glycerophosphatidylethanolamines 
(P<0.001) compared with SAT. By contrast, a significant 
decrease in monoglycerides and Coenzyme-Q6 was 
observed in EAT versus SAT (Figure 2). No difference 
was observed for other glycerolipids and for the satu-
rated of fatty acids. No correlation was found between 
lipid species of EAT and SAT.
Likewise, pathway analysis showed a significant 
enrichment in sphingolipid metabolism in EAT versus 
SAT (P<0.001, Figure II in the Data Supplement).
Differences Between SAT Lipidome of CAD and 
Non-CAD Patients
Using the same methodology, no difference was 
observed in the 295 annotated lipid species found in the 
SAT between patients with and without CAD (Figure 3).
Differences Between EAT Lipidome of CAD and 
Non-CAD Patients
Using PLS approach and variable importance in the 
projection value, we identified 97 lipid species that dis-
criminated patients with and without CAD (cutoff variable 
importance in the projection 0.88; Figure 4A and 4B, 
Table I in the Data Supplement). Among these phospha-
tidylethanolamine 18:0p/20:4 was the most important. 
Dendrogram analysis confirmed that patients with and 
without CAD clustered differently (Figure 4C). Patients 
with CAD exhibited more ceramides (P=0.01), diglycer-
ides (P=0.004; saturated and nonsaturated), monoglyc-
erides (P=0.013) in their EAT than patients without CAD. 
Conversely, they had lesser total TGs, mainly unsatu-
rated (P=0.02). Long-chain fatty acids were increased 
in unsaturated monoglycerides and medium and long-
chain fatty acids were found significantly increased 
in diglycerides in CAD versus non-CAD (all P<0.05). 
Figure 1. Orthogonal partial least squares (O-PLS) graph demonstrating a differential effect of adipose tissue location 
(epicardial adipose tissue [EAT] versus subcutaneous adipose tissue [SAT]) on lipidomic profiles.
Red spots represent samples from epicardial adipose tissue EAT and green spots represent samples from subcutaneous adipose tissue. Model 
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Table 2. Statistical Paired Analysis Reveals 95 Lipid Species Differentially Expressed Between EAT and 
SAT in the Whole Group (n=39)
Lipid Species m/z Ratio P Value FDR Fold Change EAT vs SAT
PE 18:1p/22:6 752.56 1.19×10−5 3.06×10−4 23.72 Up
PE 18:0p/20:4 774.54 3.25×10−5 4.56×10−4 5.44 Up
PE 18:0/20:3 768.55 1.15×10−5 3.06×10−4 4.86 Up
PC 16:0/20:4 782.57 2.03×10−5 3.74×10−4 3.35 Up
DG 37:6 649.48 1.59×10−5 3.14×10−4 3.31 Up
PE 16:0p/20:4 724.53 6.29×10−4 3.87×10−3 3.04 Up
TG 18:1/22:4/22:6 998.82 7.89×10−8 1.16×10−5 2.80 Up
TG 4:0/16:0/22:6 728.58 8.56×10−3 2.94×10−2 2.77 Up
PE 18:0p/18:2 728.56 1.06×10−3 5.28×10−3 2.75 Up
TG 4:0/16:0/18:1 687.55 1.35×10−5 3.07×10−4 2.70 Up
TG 45:4 774.66 2.02×10−3 8.90×10−3 2.63 Up
Cer d18:2/18:0 564.54 6.15×10−10 1.81×10−7 2.61 Up
TG 16:0/8:0/22:6 784.65 3.88×10−4 2.54×10−3 2.54 Up
TG 6:0/16:0/22:6 756.61 1.16×10−2 3.72×10−2 2.53 Up
TG 16:0/22:6/22:6 968.77 7.07×10−4 4.09×10−3 2.49 Up
Cer d18:1/18:0 566.55 1.29×10−7 1.27×10−5 2.40 Up
TG 43:4 746.63 3.20×10−3 1.31×10−2 2.38 Up
TG 11:0/18:2/18:3 800.68 9.97×10−4 5.16×10−3 2.33 Up
TG 17:4/16:1/16:1 826.69 6.25×10−3 2.41×10−2 2.29 Up
TG 47:6 798.66 3.65×10−4 2.50×10−3 2.29 Up
TG 4:0/16:0/17:1 668.58 8.56×10−3 2.94×10−2 2.16 Up
PE 18:0p/18:1 730.57 1.32×10−3 6.47×10−3 2.16 Up
TG 16:0/10:0/22:6 812.68 7.07×10−4 4.09×10−3 2.12 Up
TG 16:0/8:0/20:4 760.65 4.13×10−4 2.65×10−3 2.12 Up
TG 8:0/18:1/20:4 786.66 6.54×10−3 2.41×10−2 2.10 Up
PE 36:1 746.57 1.29×10−4 1.08×10−3 2.06 Up
TG 18:1/22:6/22:6 994.79 5.91×10−5 6.46×10−4 2.06 Up
PE 18:1/18:1 744.55 6.25×10−3 2.41×10−2 2.05 Up
Cer d18:1/24:1 648.63 1.47×10−4 1.21×10−3 2.01 Up
TG 18:0/18:1/22:6 950.82 1.47×10−5 3.10×10−4 1.99 Up
PC 32:2 730.54 7.49×10−4 4.25×10−3 1.99 Up
TG 45:5 772.64 5.19×10−3 2.10×10−2 1.99 Up
TG 16:0/16:0/22:6 896.77 3.78×10−5 4.85×10−4 1.94 Up
Cer d18:0/16:0 540.54 2.50×10−4 1.84×10−3 1.94 Up
TG 22:4/18:2/22:6 996.80 3.51×10−5 4.70×10−4 1.92 Up
Cer d18:2/20:0 592.57 8.91×10−4 4.69×10−3 1.91 Up
TG 16:0/14:0/22:6 868.74 6.84×10−5 6.96×10−4 1.90 Up
TG 14:0/18:2/22:6 892.73 6.54×10−3 2.41×10−2 1.88 Up
SM d41:1 801.68 2.84×10−4 2.04×10−3 1.85 Up
TG 18:0/16:0/22:6 924.80 2.05×10−4 1.64×10−3 1.80 Up
PE 18:0p/22:6 776.56 6.36×10−5 6.70×10−4 1.78 Up
TG 16:0/12:0/22:6 840.71 4.39×10−4 2.75×10−3 1.73 Up
DG 18:0/22:4 690.60 7.94×10−4 4.26×10−3 1.72 Up
TG 18:1/20:3/22:6 972.80 2.09×10−6 1.23×10−4 1.71 Up
PEt 15:0/18:1 689.51 1.47×10−3 6.99×10−3 1.71 Up
TG 16:0/18:1/22:6 922.79 1.25×10−5 3.06×10−4 1.71 Up
TG 6:0/17:1/18:2 720.61 2.34×10−4 1.77×10−3 1.71 Up
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TG 15:0/18:1/22:6 908.77 5.91×10−5 6.46×10−4 1.65 Up
TG 16:0/18:2/22:6 920.77 7.49×10−6 2.45×10−4 1.64 Up
TG 18:1/18:1/22:5 950.82 1.06×10−2 3.49×10−2 1.56 Up
TG 18:1/18:2/20:2 926.82 1.20×10−4 1.04×10−3 1.53 Up
TG 52:4e 858.79 5.70×10−3 2.27×10−2 1.52 Up
TG 18:1/18:1/22:3 954.84 3.43×10−4 2.41×10−3 1.51 Up
PE 34:1 718.54 3.20×10−3 1.31×10−2 1.51 Up
TG 16:0e/16:1/18:2 832.78 1.37×10−2 4.30×10−2 1.49 Up
TG 18:0/18:1/22:4 954.85 2.02×10−3 8.90×10−3 1.47 Up
TG 16:0/22:5/22:6 970.79 3.05×10−6 1.50×10−4 1.46 Up
TG 18:2/22:6/22:6 992.77 1.47×10−3 6.99×10−3 1.43 Up
TG 17:0/18:2/22:6 934.78 8.95×10−3 3.03×10−2 1.34 Up
TG 16:0e/18:1/22:5 910.82 6.84×10−3 2.49×10−2 1.33 Up
TG 17:4/12:0/12:0 718.60 1.06×10−2 3.49×10−2 1.31 Up
TG 20:1/18:1/20:2 956.85 9.75×10−5 9.59×10−4 1.12 Up
DG 16:0/20:4 634.54 9.76×10−3 3.27×10−2 1.01 Up
TG 18:2/17:1/18:2 884.77 1.06×10−3 5.28×10−3 0.77 Down
PE 16:0e 454.29 1.64×10−3 7.54×10−3 0.74 Down
DG 14:0/14:0 530.48 2.89×10−3 1.24×10−2 0.70 Down
TG 19:0/18:1/20:1 946.87 1.31×10−2 4.17×10−2 0.68 Down
DG 15:0/18:2 596.53 7.94×10−4 4.26×10−3 0.64 Down
TG 18:3/18:2/18:2 894.75 1.43×10−2 4.44×10−2 0.63 Down
TG 15:0/18:2/18:3 856.74 6.54×10−3 2.41×10−2 0.61 Down
TG 6:0/12:0/18:1 654.57 8.56×10−3 2.94×10−2 0.59 Down
TG 16:0/18:1/23:1 946.88 2.78×10−5 4.11×10−4 0.58 Down
TG 18:1/18:2/22:0 958.88 7.83×10−3 2.78×10−2 0.58 Down
MG 26:4 463.38 7.49×10−3 2.70×10−2 0.57 Down
TG 18:0/18:1/19:0 920.86 4.40×10−5 5.41×10−4 0.54 Down
TG 18:0/16:0/24:0 964.93 1.16×10−2 3.72×10−2 0.45 Down
TG 16:0/18:1/23:0 948.90 2.38×10−5 3.90×10−4 0.44 Down
TG 18:0/16:0/24:1 962.91 2.62×10−3 1.13×10−2 0.42 Down
TG 18:0/18:1/23:0 976.92 1.12×10−4 1.00×10−3 0.40 Down
TG 18:1/18:2/23:0 972.90 9.47×10−7 6.98×10−5 0.40 Down
TG 18:1/18:1/24:0 988.93 7.07×10−4 4.09×10−3 0.39 Down
TG 20:1/18:1/18:1 935.80 1.82×10−3 8.25×10−3 0.38 Down
TG 18:1/18:1/23:0 974.91 6.29×10−6 2.32×10−4 0.37 Down
TG 27:0/18:1/18:1 1030.97 1.05×10−4 9.64×10−4 0.36 Down
TG 26:0/18:1/18:2 1014.94 6.29×10−6 2.32×10−4 0.36 Down
TG 26:1/16:0/18:0 990.94 3.04×10−3 1.28×10−2 0.35 Down
Co Q6 591.44 1.55×10−3 7.26×10−3 0.34 Down
TG 26:1/18:0/18:1 1016.96 7.94×10−4 4.26×10−3 0.34 Down
TG 28:0/18:1/18:1 1044.99 5.11×10−5 6.02×10−4 0.32 Down
TG 25:0/16:0/18:1 976.93 1.05×10−4 9.64×10−4 0.30 Down
TG 25:0/18:0/18:1 1004.96 2.20×10−5 3.82×10−4 0.28 Down
TG 27:0/18:1/18:2 1028.96 3.88×10−4 2.54×10−3 0.25 Down
TG 25:0/16:0/18:0 978.94 2.19×10−4 1.70×10−3 0.24 Down
DG 26:3 496.40 2.57×10−5 4.00×10−4 0.24 Down
Cer indicates ceramide; Chol, cholesterol; Co, co-enzyme; DG, diglycerides; e, ether; EAT, epicardial adipose tissue; MG, monoglycerides; 
p, plasmalogen; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; SAT, subcutaneous adipose tissue; SM, 
sphingomyelin; and TG, triglycerides.
Table 2. Continued
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Remarkably, short-chain fatty acids were observed in TG, 
mainly represented by caproic acid (TG 6:0/12:0/18:1 
and TG 6:0/16:0/17:0). Palmitic acid (16:0) was the 
fatty acid most represented in TG (Table I in the Data 
Supplement, Figure 4B and 4D). To further evaluate 
the effect of gender on EAT lipidome, we performed 
a Cooman plot analysis. There was no obvious gener-
alization of gender membership (Figure III in the Data 
Supplement), suggesting that gender effect was not a 
confounding factor in discriminating EAT lipidome in 
patients with and without CAD.
Pathway analysis further showed a specific enrich-
ment in phospholipid biosynthesis and glycerolipid 
metabolism in EAT CAD versus non-CAD patients (both, 
P=0.006; Figure II in the Data Supplement).
Subgroup Analysis: Comparison of EAT 
Lipidome to Isolated Lipoproteins (HDL and 
VLDL) Plasma Lipidome
We further performed a subgroup analysis in 17 patients 
with CAD and 10 patients without CAD gathering isolated 
TRL and HDL lipidomics. In patients with CAD, higher 
content of total lysophosphopholipids lysophosphatidyl-
choline (P=0.002) and lysophosphatidylethanolamine 
(P=0.02) in TRL were found. In this lipoprotein, lower 
content of lysophosphatidylcholine (18:2p; P=0.04) and 
higher levels of lysophosphatidylcholine (20:4), lyso-
phosphatidylcholine (38:5), and lysophosphatidylcho-
line (16:0), as well as lysophosphatidylethanolamine 
(18:1) and lysophosphatidylethanolamine (16:0), were 
observed in patients with CAD. No differences in the 
content of lipids in HDL were observed between groups, 
although patients with CAD presented higher levels of 
DG (18:1/20:4) and sphingomyelin (22:0/20:2; P=0.04; 
Figure IV in the Data Supplement).
Only 51 lipid species were found in common between 
EAT and plasma lipoproteins. Among these species, only 
5 lipids were positively correlated between EAT and lipo-
proteins and were found in the top list of the variable 
importance in the projection. The most important was 
TG 18:0/18:0/18:1 (variable importance in the projec-
tion 1.58), which was found positively correlated (r=0.45, 
P=0.019) in EAT and HDL and in EAT and VLDL (r=0.46, 
P=0.02). TG 16:1/18:1/18:2 was positively correlated in 
EAT and HDL (r=0.39, P=0.04). TG 16:0/18:1/18:2 was 
positively correlated in EAT and VLDL (r=0.42, P=0.04).
Plasmalogen Species Analysis
Plasmalogens are a class of membrane glycerophospho-
lipids containing a vinyl-ether linked alkyl chain at the 
sn-1 position of the glycerol backbone and, typically, a 
polyunsaturated fatty acyl chain at the sn-2 position. We 
found 6 plasmalogen species (all phosphatidylethanol-
amine) in the adipose tissues: phosphatidylethanolamine 
(16:0p/20:4), phosphatidylethanolamine (18:0p/18:1), 
phosphatidylethanolamine (18:0p/18:2), phosphatidyl-
ethanolamine (18:0p/22:6), phosphatidylethanolamine(1
8:1p/22:6), and phosphatidylethanolamine (18:0p/20:4) 
and 17 in the isolated lipoproteins (6 phosphatidylcho-
line and 11 phosphatidylethanolamine; Figure 5).
Remarkably, we found that plasmalogen species 
were significantly enriched in EAT compared with SAT 
in paired analysis. No difference was observed in CAD 
versus non-CAD patients for EAT, SAT, or plasma isolated 
lipoproteins (Figure 5).
DISCUSSION
The present study sheds new light on the lipidomic signa-
ture of EAT in the context of CAD. We observed a marked 
difference in the lipidome of adipose tissues depending 
on their epicardial or subcutaneous origin. EAT and SAT 
had a totally different lipidomic profile, with 95 lipid spe-
cies differentially accumulated between the 2 tissues. 
A specific enrichment in sphingolipids (ceramides with 
18 carbons, sphingomyelin), phosphatidylcholine, phos-
phatidylethanolamine, and phosphatidylethanolamine 
plasmalogens was observed in EAT compared with SAT. 
Furthermore, we observed a specific lipidomic signature 
of EAT in CAD compared to non-CAD patients, in con-
trast to SAT. We uniquely identified 97 lipid species that 
discriminated patients with and without CAD. Patients 
with CAD exhibited more ceramides, diglycerides, mono-
glycerides, and less unsaturated TGs in their EAT than 
patients without CAD. Finally, we observed that the EAT 
Figure 2. Paired comparison of the lipidomic profile (lipid 
species) of epicardial versus subcutaneous adipose tissue 
(n=39).
Cer indicates ceramide; Chol, cholesterol; Co, co-
enzyme; DG, diglycerides; EAT, epicardial adipose tissue; 
MG, monoglycerides; PC, phosphatidylcholine; PE, 
phosphatidylethanolamine; PG, phosphatidylglycerol; SAT, 
subcutaneous adipose tissue; SM, sphingomyelin; and TG, 
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lipidome was only partially reflected by the plasma lipo-
proteins (HDL and VLDL) lipidome. Only 51 lipid spe-
cies were found in common between EAT and plasma 
lipoproteins, and only 5 lipid species were correlated 
between EAT and isolated plasma VLDL or HDL.
Importantly, we found that the EAT lipidome was inde-
pendent to that of SAT, that could indicate a specific high 
metabolic activity, or a beige associated phenotype. This 
is also illustrated by differences in the content of specific 
lipid species. It concentrated more C20 polyunsaturated 
lipid species, less C18 unsaturated ones, and less very 
long-chain saturated fatty acids. This underlined a dif-
ferent metabolic activity, such as desaturation and elon-
gation, or esterification. The presence of higher content 
in short- to medium-chain saturated fatty acids is also 
noteworthy. These fatty acids are excellent substrate 
for mitochondrial β-oxidation since they bypassed the 
carnitine transport step into the mitochondria.22 Their 
higher content in EAT could be thus helpful to deliver a 
rapid and efficient source of energy to the myocardium. 
Furthermore, the significant increase of phosphatidyl-
ethanolamine plasmalogen species in EAT is remarkable 
in that recent work from Park et al,23,24 nicely demon-
strated that peroxisome-derived lipids, such as plas-
malogens, are able to regulate adipose thermogenesis 
by mediating cold-induced mitochondrial fission. In this 
work, inhibition of peroxisomal biogenesis through 
adipose-specific knockout of the peroxisomal biogen-
esis factor Pex16 impaired cold-induced mitochon-
drial fission and resulted in severe cold intolerance 
and increased diet-induced obesity. Mechanistically, 
these effects were caused by impaired peroxisomal 
synthesis of ethanolamine plasmalogens. Since EAT 
has been shown to exhibit a beige signature,25,26 with a 
Figure 3. Unpaired comparison of the lipidomic signature of subcutaneous adipose tissue in coronary artery disease (CAD) and 
non-CAD patients.
Cer indicates ceramide; Chol, cholesterol; Co, co-enzyme; DG, diglycerides; MG, monoglycerides; PC, phosphatidylcholine; PE, 
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2-fold increase in PRDM-16 and PGC-1α, one could 
hypothesize that phosphatidylethanolamine plasmalo-
gens may be implicated in brown activation of EAT 
through the regulation of mitochondrial dynamics, but 
this deserves further investigation.
With respect to lipid quantification, adipose tissues 
are particularly challenging because of their high con-
tent of neutral lipids (>99% of triacylglycerols and cho-
lesterol esters) that causes high ion suppression of less 
abundant membrane lipids.27 TGs are located in adipo-
cyte lipid droplets, which are dynamic organelles related 
to vesicle trafficking, cell signaling, and crucial for lipid 
homeostasis.28 Up to date, wide-scale lipid profiling has 
been difficult to assess because the diversified physical 
properties of lipid metabolites require a variety of puri-
fication systems. The evolution of lipidomics has driven 
the development of new analytic platforms, specifically 
in the area of MS, that have allowed many more lipid 
Figure 4. Unpaired comparison of the lipidomic signature of epicardial adipose in coronary artery disease (CAD; n=25) and non-
CAD patients (n=14).
A, Partial least squares (PLS)-DA obtained from selected lipid species with variable importance in the projection (VIP) value greater than 
0.88, PLS-DA validation with permutation test P<0.001. B, Selection of lipid species from the VIP values at the inflection point of the curve, 
VIP value cutoff=0.88—Top 20 VIP lipid species in patients with CAD. C, Heatmap representation of hierarchical clustering of molecular 
features found in each sample of epicardial adipose tissue (EAT) of patients with and without CAD. Red, patients with CAD; green, patients 
without CAD. Coloration by lipid species abundance intensity in arbitrary units. D, Relative quantification of lipid families in EAT of patients 
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species to be analyzed in detail.13 Recently, Tomášová 
et al,29 performed minor lipids profiling in subcutane-
ous and epicardial fat of 10 patients with CAD tissue 
using liquid chromatography-MS with detachment of TG 
by thin-layer chromatography. With this novel preanalyti-
cal step, they detected only 37 lipids. Besides, a higher 
content of phosphatidylcholine and a decreased level of 
phosphatidylethanolamine (18:0/20:4) was found in EAT 
compared with SAT; the authors interpret this result as a 
smaller lipid droplet formation in EAT, as phosphatidyl-
choline/phosphatidylethanolamine ratio is essential for 
the size of the monolayer of phospholipids that covers 
the lipid droplet.29 Conversely, we observed an increased 
content in phosphatidylcholine and phosphatidylethanol-
amine in EAT versus SAT, which may reflect a high pro-
portion of cells membranes in EAT.30 Our observation is 
in agreement with histological studies showing that epi-
cardial adipocytes were significantly smaller than those 
in subcutaneous and peritoneal fat.31
Lipidomics of adipose tissues is receiving increasing 
attention, and previous studies have provided convincing 
evidence of the dynamic nature of these tissues, decipher-
ing the complex interplay between intratissue bioactive lip-
ids composition such as DG and ceramides and insulin 
resistance or type 2 diabetes mellitus.32,33 However, EAT 
often seen as a visceral proxy, is also a unique pericoro-
nary fat depot with a high lipogenic and lipolytic activity 
that could play a pivotal role in atherogenesis.34 In a recent 
meta-analysis including >40 000 low-to-intermediate car-
diovascular risk subjects, EAT volume was independently 
associated with coronary artery stenosis, myocardial isch-
emia, and major adverse cardiovascular events.35 EAT in 
CAD displays a proinflammatory phenotype, with high 
levels of reactive oxygen species and a specific pattern 
of microRNA.3 Epicardial adipocytes have intrinsic athero-
genic and proinflammatory secretion profiles.36,37 Evaluat-
ing the content of bioactive lipids within EAT in the context 
of CAD was, therefore, crucial. In 2003, Mazurek et al4 
showed that EAT exhibited significantly higher levels of 
chemokines (ie, MCP [monocyte chemotactic protein]-1) 
and several inflammatory cytokines IL (interleukin)-6, TNF 
(tumor necrosis factor)-α, and IL-1β than SAT in patients 
with CAD.4 The presence of these inflammatory media-
tors was hypothesized to accentuate plaque instability via 
apoptosis (TNF-α), vascular inflammation, and neovascu-
larization (MCP-1). Periadventitial application of endotoxin, 
MCP-1, IL-1β, or oxidized LDL (low-density lipoprotein) 
induces inflammatory cell influx into the arterial wall, 
Figure 5. Comparison of the plasmalogen lipidomic profile in adipose tissue (n=39) and isolated lipoproteins (HDL [high-
density lipoprotein] and VLDL [very low-density lipoprotein], n=27).
Paired comparison between subcutaneous vs epicardial adipose tissue (SAT vs EAT); unpaired comparison between SAT and EAT in coronary 
artery disease (CAD) and non-CAD patients; unpaired comparison between plasma isolated HDL or VLDL in CAD and non-CAD patients. 
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Table 3. Pearson or Spearman Correlation Between Common Lipids Found in Isolated Plasma HDL/VLDL Ver-
sus EAT (n=27 Patients, 17 CAD and 10 NCAD Patients)
Lipid Species
EAT vs HDL EAT vs VLDL EAT CAD vs NCAD EAT CAD vs NCAD
r P Value r P Value Regulation Significative VIP
PE 18:0p/20:4 0.19 0.332 0.27 0.201 Up 2.29
TG 18:0/18:0/18:1 0.45 0.019 0.46 0.024 Up 1.58
TG 16:1/18:1/18:2 0.39 0.043 0.19 0.366 Up 1.52
TG 16:0/18:1/18:2 0.04 0.849 0.42 0.041 Down 1.47
PE 16:0p/20:4 0.01 0.974 0.10 0.642 Up 1.45
TG 16:0/17:0/18:1 −0.21 0.296 −0.22 0.302 Up 1.21
TG 18:0/17:0/18:1 0.36 0.065 0.37 0.076 Up 1.10
TG 18:0/16:0/18:1 −0.18 0.370 −0.11 0.599 Down 1.08
PE 18:0/20:3 0.10 0.615 0.12 0.578 Up 1.08
TG 15:0/18:2/18:3 0.39 0.047 −0.02 0.929 Up 1.03
TG 18:0/16:0/16:0 −0.27 0.182 −0.28 0.192 Down 0.97
TG 18:1/18:1/18:2 0.04 0.835 0.27 0.209 Down 0.97
DG 16:0/18:1 −0.06 0.753 −0.20 0.351 Up 0.96
TG 18:2/18:2/22:6 0.35 0.072 0.24 0.260 Up 0.93
DG 16:0/16:0 −0.04 0.842 −0.06 0.768 Up 0.93
DG 18:0/16:0 0.27 0.180 0.23 0.284 Up 0.92
DG 18:1/18:2 −0.23 0.239 −0.21 0.330 Up 0.92
DG 18:1/20:4 0.14 0.475 0.20 0.360 Up 0.92
TG 16:0/18:1/22:6 0.60 0.001 0.65 0.001 Up 0.91
DG 18:0/18:1 −0.17 0.399 −0.17 0.419 Up 0.90
Cer d18:1/24:1 0.13 0.522 −0.07 0.759 Up 0.90
TG 15:0/18:1/22:6 0.40 0.039 0.50 0.013 Up 0.89
Cer d18:1/16:0 −0.11 0.585 0.02 0.935 Up 0.88
TG 16:1/14:1/18:2 0.18 0.377 0.07 0.731 Up /
TG 16:0/17:0/18:2 −0.13 0.524 −0.14 0.519 Down /
MG 18:2p −0.01 0.947 −0.13 0.557 Up /
DG 18:2/18:2 −0.43 0.026 −0.16 0.443 Up /
PE 18:1p/22:6 0.10 0.614 0.16 0.460 Up /
TG 18:0e/16:0/18:1 −0.25 0.209 −0.05 0.834 Up /
DG 18:0/18:0 0.32 0.100 0.15 0.478 Up /
Cer d18:1/22:0 0.11 0.579 0.17 0.433 Up /
TG 18:1/17:1/18:2 0.10 0.624 0.15 0.498 Down /
TG 18:2/17:1/18:2 0.35 0.076 0.46 0.023 Down /
TG 8:0/10:0/10:0 0.33 0.096 0.00 0.987 Up /
Cer d18:2/22:0 −0.04 0.836 0.15 0.476 Up /
Chol 0.13 0.510 0.09 0.692 Up /
PC 16:0/20:4 0.61 0.001 0.23 0.271 Up /
PE 18:0p/18:1 0.16 0.413 0.27 0.205 Up /
SM d41:1 −0.14 0.473 −0.21 0.324 Down /
TG 15:0/16:0/18:2 −0.58 0.002 −0.51 0.011 Up /
TG 15:0/18:2/18:2 −0.35 0.072 −0.38 0.067 Down /
TG 16:0/14:0/16:1 −0.12 0.536 −0.15 0.491 Down /
TG 16:0/18:1/22:5 0.55 0.003 0.36 0.087 Up /
TG 16:0/18:2/22:6 0.28 0.152 0.42 0.043 Up /
TG 16:1/18:2/18:3 0.48 0.011 0.43 0.035 Down /
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coronary vasospasm, or intimal lesions. This provides 
evidence that bioactive molecules from the pericoronary 
tissues may alter arterial homeostasis.38 These observa-
tions tended to support the concept of outside-to-inside 
cellular cross-talk in that inflammatory mediators or FFAs 
produced by EAT adjacent to the coronary artery, may 
have a paracrine toxic effect on the vasculature, in diffus-
ing passively or via vasa vasorum through the vessel wall.3 
Using a pangenomic approach, we previously identified 
that EAT was particularly enriched in inflammation, extra-
cellular matrix remodeling, immune signaling, thrombosis, 
beiging, coagulation, and apoptosis pathways.39 Moreover, 
we demonstrated that Secretory Type II Phospholipase 
A2, which catalyzes the rate-limiting step in formation of 
proinflammatory lipid mediators, was highly expressed 
and secreted in the EAT of patients with CAD.40 In this 
study, we bring further evidence that EAT is specifically 
enriched in ceramides, compared to SAT and in the con-
text of CAD (in particular Cer d18). Ceramides are precur-
sors for the predominant sphingolipids in the cell, including 
sphingomyelin and gangliosides. Sphingolipids are not 
absorbed from dietary sources but are instead produced 
from breakdown products of saturated fats (ie, palmitate) 
and proteins (ie, serine) via the action of serine palmitoyl-
transferase.41 Many of them play important roles in cellular 
growth and function, with ceramides receiving the great-
est attention, as they participate in numerous inflammatory 
processes, and have been found to disrupt insulin sen-
sitivity, impair β-cell function, vascular reactivity, or mito-
chondrial metabolism, inducing cellular dysfunction, and 
apoptosis (lipotoxicity).41,42 Ceramide 1-phosphate has 
been shown to mediate inflammatory responses by pro-
moting phospholipase A2-mediated eicosanoid storm and 
by inducing cytokine production.43,44 Ceramides activate 
the nucleotide-binding domain, leucine-rich-containing 
family, pyrin domain-containing-3 NLRP3 inflammasome, 
which activates caspase 1 and mediates the processing 
and release of IL-1β, the expression of which in EAT was 
predictive of CAD.11,45 Acute generation of ceramide by 
sphingomyelinases is able to induce lipoproteins aggrega-
tion.46 Ceramide is also implicated in oxidized LDL tran-
scytosis across endothelial cells, thus being implicated 
in the retention of bioactive lipids in the vascular wall.47 
Last, endogenous ceramides regulate monocyte adhe-
sion to vessel walls and then promotes atheroma plaque 
development.48 Interestingly, the treatment of apo-E defi-
cient mice with myriocin, the serine palmitoyltransferase 
inhibitor, and subsequent de novo ceramide synthesis, 
resulted in the 40% lowering of preformed atherosclerotic 
lesions.49 These data are consistent with a specific role of 
ceramide in lipid-induced atherogenesis and inflammation. 
These lipids within the adipose tissue may participate in 
the induction of EAT inflammation, may also directly mod-
ulate vascular inflammation by outside-to-inside cellular 
cross-talk. Finally, they may directly act on myocardium (as 
there is no fascia separating epicardial adipocytes from 
cardiomyocytes) to participate in inflammation and modu-
late heart function.41,42
In this study, we identified specific lipidomic signature 
of isolated VLDL in CAD. VLDL from patients with CAD 
showed higher content of total lysophosphopholipids 
with lower content of monoglyceride (18:2p). However, 
no differences in the total content of each lipid in HDL 
were observed between patients with and without CAD. 
Remarkably, we observed that the EAT lipidome in CAD 
was only partially reflected by the plasma lipoproteins 
(HDL and VLDL) lipidome. Only 51 lipid species were 
found in common between EAT and plasma lipoproteins, 
and only 5 lipid species were correlated between EAT 
and isolated plasma VLDL or HDL. These data indicate 
that plasma isolated lipoproteins lipidomic profile does 
not entirely reflect the EAT lipidome and cannot be used 
as EAT bioactive lipid content biomarker.
Several limitations of our study should be noted. 
This was an observational study, with patients with CAD 
exhibiting more cardiovascular risk factors (smoking, 
diabetes mellitus, and higher TGs) than patients without 
CAD. These differences may have influenced our results. 
Some authors reported reduction in fatty acid (16:0) and 
an increase in (18:0, and conjugated linoleic acid) and 
a decrease of (18:1n-11, 20:5n-3, and 22:6n-3) in the 
EAT of diabetics.9 Others have found a positive associa-
tion between EAT volume and density (which reflects the 
tissue cellularity), diabetes mellitus, and active smoking.50 
Finally, Błachnio-Zabielska et al,33 specifically described 
the bioactive lipids content of SAT and EAT in obese 
TG 18:0/16:0/17:0 0.46 0.015 0.37 0.079 Up /
TG 18:0/16:0/18:0 0.51 0.007 0.27 0.201 Up /
TG 18:3/18:2/18:2 0.24 0.224 0.32 0.125 Up /
TG 8:0/8:0/10:0 −0.07 0.746 −0.27 0.200 Up /
TG 8:0/8:0/8:0 −0.04 0.856 −0.14 0.527 Up /
CAD indicates coronary artery disease; Cer, ceramide; Chol, cholesterol; Co, co-enzyme; DG, diglycerides; e, ether; EAT, epicardial adipose tissue; 
HDL, high-density lipoprotein; MG, monoglycerides; p, plasmalogen; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; 
SM, sphingomyelin; TG, triglycerides; VIP, variable importance in the projection value; and VLDL, very low-density lipoprotein.
Table 3. Continued
Lipid Species
EAT vs HDL EAT vs VLDL EAT CAD vs NCAD EAT CAD vs NCAD
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diabetic, compared to lean nondiabetic, and obese nondi-
abetic subjects and found a positive correlation between 
C16:0-CoA content and HOMA-IR in EAT.33 While we 
have discussed the evidence for a potential pathogenic 
role of bioactive lipids within EAT in CAD, future studies 
are needed to determine whether these lipids dynami-
cally change the physiology of the arterial wall and are 
directly implicated in the development of atherogenesis.
Future Directions
This study brings new insight in the importance of ecto-
pic adipose tissue lipids compared to classical plasma 
lipids in CAD pathophysiology. Future studies should 
focus on the characterization of these ectopic lipids and 
their role in inflammatory processes or thermogenesis. 
The development of new imaging techniques to assess 
non invasively EAT is warranted to ameliorate clinical 
practices and improve personalized medicine.
Conclusions
In this study, we uniquely demonstrated that CAD is asso-
ciated with a specific lipidomic signature of EAT, unlike 
SAT, with a specific enrichment in ceramides, diglycerides 
monoglycerides, and less unsaturated TGs than patients 
without CAD. This increase in lipotoxic lipids could partic-
ipate in the inflammation of the adjacent coronary artery 
wall and in the pathophysiology of CAD. Furthermore, we 
observed that the EAT lipidome in CAD was only partially 
reflected by the plasma lipoproteins (HDL and VLDL) 
lipidome, suggesting that plasma lipidome is not the bio-
marker of this ectopic dynamic organ.
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